David Schaffer is Director at 4D Molecular Therapeutics Inc. (FDMT). They have made 7 open-market trades across 2 companies since 2018, most recently 2021-10-22.
CIK 0001692929
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FDMT | SELL | 2021-10-20 | 2021-10-22 | $31.37 | $2.2M | -22.7% | -28.3% | -54.0% |
| FDMT | SELL | 2021-09-29 | 2021-10-01 | $27.86 | $1.6M | +3.2% | -5.7% | -14.5% |
| FDMT | SELL | 2021-09-27 | 2021-09-29 | $31.90 | $2.1M | -6.5% | -13.7% | -22.6% |
| QURE | SELL | 2020-01-28 | 2020-01-30 | $62.27 | $100K | +5.1% | -7.8% | +7.2% |
| QURE | SELL | 2019-01-28 | 2019-01-30 | $31.31 | $38K | +13.0% | +74.0% | +70.6% |
| QURE | SELL | 2019-01-17 | 2019-01-29 | $30.71 | $230K | +13.2% | +67.5% | +75.7% |
| QURE | SELL | 2018-01-29 | 2018-01-31 | $18.53 | $107K | +20.8% | +43.9% | +61.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.